Revelation Biosciences, Inc. - Common Stock (NQ:REVB)

3.535 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Revelation Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Crude Oil Falls Over 1%; Best Buy Reports Downbeat Results ↗

May 29, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

May 29, 2025

Via Benzinga

Nasdaq Gains Over 1%; Nvidia Posts Strong Revenue ↗

May 29, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 29, 2025

Via Benzinga

Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering

May 29, 2025

From Revelation Biosciences, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

May 28, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 28, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 23, 2025

Via Benzinga

Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors

May 23, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025

May 08, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients

April 29, 2025

From Revelation Biosciences, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

April 23, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 16, 2025

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

April 09, 2025

Via Benzinga

Wondering what's happening in today's after-hours session? ↗

April 08, 2025

As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

April 08, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 08, 2025

Via Benzinga

Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗

March 17, 2025

Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis.

Via Chartmill

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 17, 2025

Via Benzinga

Traders are paying attention to the gapping stocks in Monday's session. ↗

March 17, 2025

Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps.

Via Chartmill

Which stocks are moving before the opening bell on Monday? ↗

March 17, 2025

The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 17, 2025

Via Benzinga

Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket ↗

March 17, 2025

Via Benzinga

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells

March 17, 2025

From Revelation Biosciences, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

March 14, 2025

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

March 14, 2025

Via Benzinga

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference

March 13, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024

March 06, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients

February 26, 2025

From Revelation Biosciences, Inc.

Via Business Wire

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval

February 24, 2025

From Revelation Biosciences, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.